Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Consolidated Net Income (2016 - 2025)

Amphastar Pharmaceuticals has reported Consolidated Net Income over the past 13 years, most recently at $58.4 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at $58.4 million for Q4 2025, up 34.67% from a year ago — trailing twelve months through Dec 2025 was $132.1 million (down 20.2% YoY), and the annual figure for FY2025 was $132.1 million, down 20.2%.
  • Consolidated Net Income for Q4 2025 was $58.4 million at Amphastar Pharmaceuticals, up from $17.3 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for AMPH hit a ceiling of $58.4 million in Q4 2025 and a floor of -$145.2 million in Q4 2023.
  • Median Consolidated Net Income over the past 5 years was $25.9 million (2023), compared with a mean of $14.4 million.
  • Biggest five-year swings in Consolidated Net Income: soared 703.36% in 2021 and later tumbled 494.19% in 2022.
  • Amphastar Pharmaceuticals' Consolidated Net Income stood at $23.7 million in 2021, then tumbled by 494.19% to -$93.2 million in 2022, then tumbled by 55.79% to -$145.2 million in 2023, then soared by 129.86% to $43.4 million in 2024, then soared by 34.67% to $58.4 million in 2025.
  • The last three reported values for Consolidated Net Income were $58.4 million (Q4 2025), $17.3 million (Q3 2025), and $31.0 million (Q2 2025) per Business Quant data.